£197m Payments Made Under New UK Pricing Scheme But Access Promises Still To Materialize
Payments have now been made under the UK’s 2019 pricing and access to branded medicines scheme, but industry will have to wait longer for promises on access to materialize.
You may also be interested in...
The Pink Sheet’s freedom of information request relating to the 2019 pricing and access to branded medicines scheme has shed light on the metrics being used to gauge whether the scheme is delivering on its promise.
The UK government will consider all options to improve access to Vertex’s cystic fibrosis treatment, including compulsory licensing.
The revised PPRS, which is expected to take effect at the beginning of 2019, will implement a 2% cap on the growth in sales of branded medicines to the NHS that should result in substantial savings on medicines spending. It also provides for faster NICE appraisals for non-cancer drugs, and more flexibility in commercial discussions between companies and the health department.